Global Biosimilar Market is expected to grow at a CAGR of 27.1% from 2017 to 2025

The ” Global Biosimilar market, By Recombinant Products (Non-Glycosylated Proteins, Glycosylated Proteins, peptides and others) By Application (Oncology, Blood Disorders, Chronic and Auto-immune Disease, infectious diseases and others) opportunities and forecast 2017-2025″ report has been added to Reports Monitor’s database.

The study for Biosimilar Market will provide market size, estimates and forecast based on the following years:

Historic data: 2015

Base Year Estimate: 2016

Forecast: 2017 to 2025

Biosimilars are the copied version of biologics that have undergone patent expiration. The major factors that are driving the growth of the market includes  increasing demand for these drugs due to rising geriatric population, their cost-effectiveness, strategic collaborations ensuring enhanced throughput and clinical trial activities for these drugs, and increasing support from the government  and initiatives to develop and promote these drugs.

Get a Free Sample of this Report @

Europe has around 27 biosimilar drugs available, US has been slower to hold on this trend. Recently, the growth is accelerating due to patent expiration of popular biologics. Also, it is expected that the rising acceptance of these drugs by governments and physicians, and the growth of real-world evidence will help build patient confidence and trust with regards to the efficacy and safety of these products. This, in turn will drive growth in the market. Furthermore, as the price of these drugs is 30 to 50 per cent lower than the originals, there exist huge potential healthcare cost savings, which will also drive the market for these copied drugs. Currently, there are more of these drugs in progress across the Asia-Pacific than anywhere else, leading to numerous great opportunities. Producers of these drugs in Asian countries share various benefits over their competitors in US and EU markets.

Have a query on this Report? Speak to Analyst @

Over the next three to four years, it will be significantly easier to obtain sanction for these drugs development in the U.S. The faster drug makers can get these drugs through the governing agencies, and as the cost of developing these drugs decreases, the greater the chances will be for more firms to step in and create impact on the industry. With more players producing these drugs, there will be more options which mean a bigger number of people will be able to obtain the benefits, these drugs provide. Also, it is expected that the market won’t be able to withstand the large number of participants in the long term, hence it is expected that only the most successful businesses sustaining a presence. Companies like Teva and Coherus, Sandoz are anticipated to show a great deal of progress over the next decade as they bring more of these products to market. This is the market that will continue to be in focus in this billion-dollar business industry with the probability of changing the industry forever.

To be successful in the sector, companies must implement the quality and latest technology initiatives, such as design of experiments, quality by design, and process analytical technology. They also take a practical approach in risk mitigation by accumulating risk management plans and accepting production best practices that are outlined by regulatory agencies and industry associations.

For more information on this report visit

About Us

Reports Monitor is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries including Healthcare, Technology, Chemicals, Materials, and Energy. With an intrinsic understanding of many business environments, Reports Monitor provides strategic objective insights.

We periodically update our market research studies to ensure our clients get the most recent, relevant, and valuable information. Reports Monitor has a strong base of analysts and consultants from assorted areas of expertise. Our industry experience and ability to zero-in on the crux of any challenge gives you and your organization the ability to secure a competitive advantage.

Contact Details


Phone: +1 513 549 5911

Leave a Reply

Your email address will not be published. Required fields are marked *